Axitinib is an Ideal Choice in Refractory Renal Cell Carcinoma

Axitinib is an Ideal Choice in Refractory Renal Cell Carcinoma

kidneycancer

3 years
749 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Brian I. Rini, M.D., Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center presents Axitinib is an Ideal Choice in Refractory Renal Cell Carcinoma.
Up Next Autoplay